← Leaderboards
Michael A. Carducci
Johns Hopkins University
$23,642,506
Attributed
$39,524,617
Total exposure
16
Grants
9
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $6.9M · FY2005–25$10M$7.5M$5M$2.5M$0
'05
'06
'07
'08
'09
'10
'11
'12
'13
'14
'15
'16
'17
'18
'19
'20
'21
'22
'23
'24
'25
Funding mix
By agency
NIH$39,524,617 · 16
By mechanism
UM1$20,058,272 · 1
P30$10,183,118 · 6
U01$8,392,899 · 1
U24$505,279 · 1
R01$172,376 · 1
N01$121,953 · 1
Top collaborators
- Michelle A Rudek15 shared
- Christopher D Gocke11 shared
- Ivana Gojo11 shared
- Ryan Gentzler6 shared
- Glenn Liu6 shared
- Wells A Messersmith4 shared
- Jimmy Ruiz3 shared
- Jan Hendrik Beumer2 shared
Most similar at Johns Hopkins University
Same institution · by research overlap
- James Sk Sham$11,220,427
- Maxine L Stitzer$35,973,273
- Leigh E Boulware$39,736,144
- Pamela L. Zeitlin$9,680,949
- Alison P Klein$15,423,583
Others in their field
Top investigators on “Clinical Research”
- David Heimbrook · Leidos Biomedical Research, Inc.$1,040,569,537
- Leonard Freedman · Leidos Biomedical Research, Inc.$975,089,882
- Lawrence Corey · Fred Hutchinson Cancer Center$739,766,552
- Sonia M Thomas · Research Triangle Institute$700,865,642
- Jeffrey P Krischer · University Of South Florida$611,867,176
- Barton F Haynes · Duke University$538,862,577
Research focus
Clinical ResearchClinical TrialsMemberResearch PersonnelComprehensive Cancer CenterLeadershipMalignant NeoplasmsProtocols DocumentationTrainingInvestigational DrugsEnsureClinical DataMonitorEvaluationOncologyProgramsEnvironmentDesignTranslational ResearchInstitutionPharmaceutical PreparationsClinical ProtocolsCollaborationsGrant
Grant awards (79)
The Johns Hopkins Translational Science Team and Consortium for ETCTN Studies$1,817,609
UM1 · FY2025 · CA · contact PI
Research Pharmacy$299,086
P30 · FY2025 · CA · contact PI
Protocol Review and Monitoring System$299,086
P30 · FY2025 · CA · contact PI
Clinical Protocol and Data Management$299,086
P30 · FY2025 · CA · contact PI
The Johns Hopkins Translational Science Team and Consortium for ETCTN Studies$1,727,315
UM1 · FY2024 · CA · contact PI
Clinical Protocol and Data Management$744,331
P30 · FY2024 · CA · contact PI
Research Pharmacy$275,834
P30 · FY2024 · CA · contact PI
Protocol Review and Monitoring System$93,791
P30 · FY2024 · CA · contact PI
The Johns Hopkins Translational Science Team and Consortium for ETCTN Studies$1,836,359
UM1 · FY2023 · CA · contact PI
Clinical Protocol and Data Management$744,331
P30 · FY2023 · CA · contact PI
The Chesapeake-Ohio Pharmacokinetics Core for The ETCTN$505,279
U24 · FY2023 · CA · contact PI
Research Pharmacy$275,834
P30 · FY2023 · CA · contact PI
Protocol Review and Monitoring System$93,791
P30 · FY2023 · CA · contact PI
Clinical Protocol and Data Management$744,331
P30 · FY2022 · CA · contact PI
The Johns Hopkins Translational Science Team and Consortium for ETCTN Studies$400,000
UM1 · FY2022 · CA · contact PI
Research Pharmacy$275,834
P30 · FY2022 · CA · contact PI
Protocol Review and Monitoring System$93,791
P30 · FY2022 · CA · contact PI
Clinical Protocol and Data Management$803,960
P30 · FY2021 · CA · contact PI
Research Pharmacy$286,563
P30 · FY2021 · CA · contact PI
The Johns Hopkins Translational Science Team for the ET-CTN$125,000
UM1 · FY2021 · CA · contact PI
The Johns Hopkins Translational Science Team for the ET-CTN$99,789
UM1 · FY2021 · CA · contact PI
Protocol Review and Monitoring System$93,338
P30 · FY2021 · CA · contact PI
The Johns Hopkins Translational Science Team and Consortium for ETCTN Studies$5,745,990
UM1 · FY2020 · CA · contact PI
Clinical Protocol and Data Management$803,960
P30 · FY2020 · CA · contact PI
Research Pharmacy$286,563
P30 · FY2020 · CA · contact PI
Protocol Review and Monitoring System$93,338
P30 · FY2020 · CA · contact PI
The Johns Hopkins Translational Science Team for the ET-CTN$1,639,503
UM1 · FY2019 · CA · contact PI
Clinical Protocol and Data Management$803,960
P30 · FY2019 · CA · contact PI
Research Pharmacy$286,563
P30 · FY2019 · CA · contact PI
Protocol Review and Monitoring System$93,338
P30 · FY2019 · CA · contact PI
The Johns Hopkins Translational Science Team for the ET-CTN$2,209,015
UM1 · FY2018 · CA · contact PI
Clinical Protocol and Data Management$803,756
P30 · FY2018 · CA · contact PI
Research Pharmacy$286,490
P30 · FY2018 · CA · contact PI
Protocol Review and Monitoring System$93,314
P30 · FY2018 · CA · contact PI
Protocol Review and Monitoring System$6,864
P30 · FY2018 · CA · contact PI
Research Pharmacy$6,864
P30 · FY2018 · CA · contact PI
Clinical Protocol and Data Management$6,864
P30 · FY2018 · CA · contact PI
Research Pharmacy$2,068
P30 · FY2018 · CA · contact PI
Protocol Review and Monitoring System$2,068
P30 · FY2018 · CA · contact PI
Clinical Protocol and Data Management$2,068
P30 · FY2018 · CA · contact PI
Clinical Protocol and Data Management$802,733
P30 · FY2017 · CA · contact PI
The Johns Hopkins Translational Science Team for the ET-CTN$300,000
UM1 · FY2017 · CA · contact PI
Research Pharmacy$286,125
P30 · FY2017 · CA · contact PI
The Johns Hopkins Translational Science Team for the ET-CTN$147,150
UM1 · FY2017 · CA · contact PI
The Johns Hopkins Translational Science Team for the ET-CTN$100,000
UM1 · FY2017 · CA · contact PI
The Johns Hopkins Translational Science Team for the ET-CTN$100,000
UM1 · FY2017 · CA · contact PI
Protocol Review and Monitoring System$93,195
P30 · FY2017 · CA · contact PI
The Johns Hopkins Translational Science Team for the ET-CTN$50,000
UM1 · FY2017 · CA · contact PI
The Johns Hopkins Translational Science Team for the ET-CTN$1,087,834
UM1 · FY2016 · CA · contact PI
The Johns Hopkins Translational Science Team for the ET-CTN$872,709
UM1 · FY2016 · CA · contact PI
The Johns Hopkins Translational Science Team for the ET-CTN$900,000
UM1 · FY2015 · CA · contact PI
The Johns Hopkins Translational Science Team for the ET-CTN$899,999
UM1 · FY2014 · CA · contact PI
Phase I Clinical Trials of New Anti-Cancer Targeted Therapies$845,109
U01 · FY2013 · CA · contact PI
Phase I Clinical Trials of New Anti-Cancer Targeted Therapies$854,997
U01 · FY2012 · CA · contact PI
Phase I Clinical Trials of New Anti-Cancer Targeted Therapies$854,997
U01 · FY2011 · CA · contact PI
Phase I Clinical Trials of New Anti-Cancer Targeted Therapies$881,441
U01 · FY2010 · CA · contact PI
Phase I Clinical Trials of New Anti-Cancer Targeted Therapies$890,075
U01 · FY2009 · CA · contact PI
Phase I Clinical Trials of New Anti-Cancer Targeted Therapies$572,797
U01 · FY2009 · CA · contact PI
Phase I Clinical Trials of New Anti-Cancer Targeted Therapies$890,065
U01 · FY2008 · CA · contact PI
Phase I Clinical Trials of New Anti-Cancer Targeted Ther$546,309
U01 · FY2007 · CA · contact PI
Phase I Clinical Trials of New Anti-Cancer Targeted Ther$395,815
U01 · FY2006 · CA · contact PI
Phase I Clinical Trials of New Anti-Cancer Targeted Ther$394,928
U01 · FY2005 · CA
Phase I Clinical Trials of New Anti-Cancer Targeted Ther$384,818
U01 · FY2004 · CA
Phase I Clinical Trials of New Anti-Cancer Targeted Ther$375,002
U01 · FY2003 · CA
Restoration of gene function in prostate cancer$0
P50 · FY2003 · CA
PHASE I TRIALS OF ANTICANCER AGENTS$223,358
U01 · FY2002 · CA
PHASE I TRIAL OF ORAL PHENYLBUTYRATE IN SOlID TUMORS$0
M01 · FY2002 · RR
DOSE/PHARMACOKINETICS OF ABT 627 IN ADENOCARCINOMA$0
M01 · FY2002 · RR
MULTIPLE DOSE STUDY OF SAFETY OF ABT 627$0
M01 · FY2002 · RR
PHASE I TRIALS OF ANTICANCER AGENTS$283,188
U01 · FY2001 · CA
DOSE/PHARMACOKINETICS OF ABT 627 IN ADENOCARCINOMA$0
M01 · FY2001 · RR
PHASE I TRIAL OF ORAL PHENYLBUTYRATE IN SOlID TUMORS$0
M01 · FY2001 · RR
MULTIPLE DOSE STUDY OF SAFETY OF ABT 627$0
M01 · FY2001 · RR
PHENYLBUTYRATE BIOACTIVITY ASSESSMENT IN PROSTATE CANCER$172,376
R01 · FY2000 · CA
A RANDOMIZED CONTROLLED PHASE II CLINICAL TRIAL OF MODUL$121,953
N01 · FY2000 · CN
GENE THERAPY FOR PROSTATE CANCER$90,720
K08 · FY2000 · CA
MULTIPLE DOSE STUDY OF SAFETY OF ABT 627$0
M01 · FY2000 · RR
DOSE/PHARMACOKINETICS OF ABT 627 IN ADENOCARCINOMA$0
M01 · FY2000 · RR
PHASE I TRIAL OF ORAL PHENYLBUTYRATE IN SOlID TUMORS$0
M01 · FY2000 · RR